Parkinson’s disease affects millions of people worldwide. Current treatments focus on relieving symptoms, but over time they lose their effectiveness and may even cause new, debilitating side effects. Moreover, they do not address the underlying disease processes, allowing the disease to progress undiminished. Parkinnova’s new therapy is designed to not only manage symptoms more effectively but also to delay disease progression, with the goal of providing a more sustainable and comprehensive treatment.

The funding from the Innovatiefonds Noord-Holland is a crucial step toward clinical trials. With this investment, Parkinnova is advancing the development and optimization of a new generation of PDE inhibitors. This includes the optimization of molecular properties and extensive preclinical testing to validate efficacy and safety. These steps are essential to select a promising candidate and lay the foundation for further clinical development.

This innovative PDE-inhibition therapy could represent a breakthrough in the treatment of Parkinson’s disease. With a targeted, innovative approach, the disease can be treated more effectively while also reducing its overall impact. This offers patients a more effective and sustainable treatment option, with fewer side effects and the potential to slow disease progression—a step toward a future in which Parkinson’s no longer dominates patients’ daily lives.